Laboratory automation makes great changes to the traditional laboratories in diagnostic testing, R&D, and production. It can process and analyze samples quickly and accurately with complete traceability.
RayKol Group Corp (Chinese: 睿科集团) completes a Series A round of financing worth more than CNY 100 million. This funding round was led by River Head Capital (Chinese: 阳光融汇资本), followed by Sherpa Healthcare Partners (Chinese: 夏尔巴投资).
Founded in 2010, RayKol is an integrated solutions provider for automated laboratories focusing on improving the efficiency of inspection and testing. The company's business includes R&D, production, sale, and third-party testing.
After this round of financing, RayKol will continue to increase R&D investment, and expand product lines such as automatic pretreatment equipment, multi-functional preparation workstation, and reagents and consumables.
Laboratory automation refers to using the automatic testing equipment to inspect and analyze samples. It could free technicians and scientists from time-consuming manual tasks and improve work efficiency. With the increasing demand for nucleic acid detection, laboratory automation has gradually attracted attention. We look forward to seeing an intelligent laboratory with the ability of self-learning and exploration, which can design, implement and modify the experimental scheme by itself in the future.
At present, many enterprises have covered the field of automation equipment, single modules, and workstations, including international giants such as Thermo Fisher, Beckman, Agilent, Roche, TECAN, and Hamilton. Chinese manufacturers such as MGI Tech (Chinese: 华大智造), ReeToo (Chinese: 瑞图生物), and Gene Point (Chinese: 基点生物) also have been involved.